Cardiovascular

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction

The US Food and Drug Administration (FDA) has granted approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg) for lowering cardiovascular risks in adults with established cardiovascular disease (CVD) who are overweight or obese.

IsomAb secures funds to advance peripheral arterial disease treatment

UK-based biotechnology company IsomAb has secured £7.5m (approximately $9.4m) in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.

Innovent and SanegeneBio partner for hypertension drug development

Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.

Amarin signs agreement with Neopharm to market VAZKEPA in Israel

Amarin has entered into an exclusive marketing and commercialisation agreement with Neopharm for VAZKEPA in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.

Eleven Therapeutics enters research collaboration with Novo Nordisk

Eleven Therapeutics has entered into a research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics.

Tenaya Therapeutics gets fast track designation for gene therapy TN-201

Clinical-stage biotechnology company Tenaya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, TN-201.

Novartis gets positive CHMP opinion for Entresto to treat paediatric heart failure

Novartis has received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended approval for the company’s Entresto (sacubitril/valsartan) to treat paediatric heart failure.

FDA grants RMAT designation to Rocket Pharmaceutical’s therapy for Danon Disease

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Rocket Pharmaceuticals’ RP-A501, an investigational adeno-associated virus (AAV)-based gene therapy to treat Danon Disease.